Methods of treatment involving p21/CIP1

a technology of rheumatoid arthritis and p21cip1, which is applied in the field of molecules for suppressing inflammation of rheumatoid arthritis, can solve the problems of little evidence proving that these drugs arrest the progression of the disease, the inability to achieve total prevention of joint destruction through conventional treatments, and the inability to achieve the effect of preventing aberrant growth and/or inflammation of synovial tissue, promoting expression or function of p21cip1 protein, and the inability to
US20080226599A1Inactive Publication Date: 2008-09-18MIYASAKA NOBUYUKI +1
2 Cites 2 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
MIYASAKA NOBUYUKI
Publication Date
2008-09-18
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p16INK4a and p21Cip1 p in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or the expression of inflammatory cytokines in synovial tissues targeting the p21Cip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.
Need to check novelty before this filing date? Find Prior Art

Description

CLAIM OF PRIORITY

[0001] This application is a continuation of U.S. patent application Ser. No. 10 / 088,661, filed on Jul. 19, 2002, which is the U.S. National Phase of International Patent Application No. PCT / JP00 / 06511, filed on Sep. 22, 2000, which claims the benefit of Japanese Patent Application No. 11-269579, filed on Sep. 22, 1999. The entire contents of each of the foregoing applications are hereby incorporated by reference.TECHNICAL FIELD

[0002] The present invention relates to molecules for suppressing inflammation of Rheumatoid arthritis (RA) and the screening of those molecules.BACKGROUND ART

[0003] Rheumatoid arthritis (RA) is characterized by the synovial inflammation of multiple joints. The affected synovial tissues contain activated macrophages, fibroblasts, T- and B-lymphocytes. The synovial fibroblasts proliferate and release tissue-degrading enzymes in response to pro-inflammatory cytokines, such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6, which are ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More